RxDoctor Payments Data

Alan Mezey, MD

Internal Medicine · Wynnewood, PANPI 1245263250

Payments from drug & device makers

$2,397in general payments, 2019–2025

Across 130 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$449
  • GSK$269
  • AbbVie$255
  • Lilly USA, LLC$224
  • Pfizer$206
  • Novo Nordisk$188
  • plus $806 from 16 others

What the payments were for

  • Food & beverage$2,397100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,397 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,688
Medicare patients
393
Services billed
1,226

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$108,524
EliquisApixaban93$85,123
JardianceEmpagliflozin59$65,529
XareltoRivaroxaban49$35,552
JanuviaSitagliptin Phosphate20$28,435
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$16,291
HorizantGabapentin Enacarbil12$12,039
Tresiba Flextouch U-100Insulin Degludec11$10,881
TrulicityDulaglutide11$10,418
MounjaroTirzepatide11$9,986
Atorvastatin Calcium689$8,291
RestasisCyclosporine11$6,985
SynthroidLevothyroxine Sodium54$4,970
PaxlovidNirmatrelvir/Ritonavir24$4,288
Amlodipine Besylate580$3,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$188$108,52473 claims
PfizerEliquis, Paxlovid$206$89,411117 claims
Boehringer IngelheimJardiance$449$65,52959 claims
Johnson & JohnsonXarelto$41$35,55249 claims
MerckJanuvia$75$28,43520 claims
Lilly USA, LLCTrulicity, Mounjaro$224$20,40522 claims
GSKTrelegy Ellipta$269$16,29115 claims
AbbVieRestasis, Synthroid$255$11,95565 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Wynnewood

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →